
pm et
summari lead manufactur gener pharmaceut produc broad rang tradit
specialti drug sold around world
price-to-earnings oper ep
risk assess reflect risk inher gener
pharmaceut busi includ uncertaini
regulatori approv legal challeng patent
brand drug howev risk partial off-set
wide divers gener portfolio
product account revenu
success track record receiv first gener
approv high-barri specialti biolog drug
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
ytd sale yoy led
reduct north america sale
total europ rest world
show solid growth ytd howev
yoy respect share
come sever pressur year due
weak north america sale
think sign stabil may emerg --
north america sale vs
sequenti
think uptak gener copaxon approv
help stabil north america
sale last six month biosimilar
neulasta white blood cell drug approv
potenti approv gener
advair asthma support north
america sale view see
import win need balanc
continu price eros gener drug
 increas competit
help off-set revenu declin
reduc ytd sg expens
yoy respect despit effort
ytd adjust pre-tax incom yoy
due materi lower gross margin
cautiou view upcom
growth catalyst potenti off-set
continu weak gener note
fda trail six-month gener
approv yoy
think indic competit remain
intens need balanc headwind
high-valu gener approv view
gener copaxon ms
continu gain market
see similar potenti neulasta
biosimilar got approv
potenti advair gener
think good strategi target
higher-barri brand drug gener
approv difficult tradit
gener maker obtain risk view
includ sever gener deflat
target price ep estim
-- histor averag forward price-to-earnings
see price pressur continu
encourag howev despit
declin sale ytd acquisit
yoy modestli
yoy think invest
need ensur long-term competit
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
gener brand name prescript over-the-count over-the-counter product variou dosag form
therapeut categori approxim market product world-wide custom
approxim countri territori
compani oper three segment north america europ rest world
market compani manufactur sell portfolio oral solid dosag inject transderm
patch gel cream ointment unit dose offer across variou key therapeut area includ
respiratori allergi infecti diseas cardiovascular oncolog central nervou system
ampoul lyophil focu oncolog penem penicillin ophthalm peptid
compani also portfolio brand gener topic product includ activ pipelin
product develop well establish sale market infrastructur target
product epipen auto-injector use treatment sever allerg reaction
epinephrin auto-injector sold intern anaphylaxi sever allerg
reaction may caus death either swell shut airway signific drop
blood pressur compani launch first author gener epipen auto-injector
drug formul devic function brand product
compani launch glatiram acet inject mg/ml three-times-a-week
inject ap-rat substitut gener version copaxon mg/ml well glatiram
acet inject mg/ml once-daili inject ap-rat substitut gener version
copaxon mg/ml product indic treatment patient relaps form
multipl sclerosi chronic inflammatori diseas central nervou system
corpor strategi key object capit compani strength global reach
vertic integr also plan focu difficult-to-develop gener specialti
pharmaceut well achiev greater economi scale manufactur compani
also seek first gener firm penetr new market captur new product opportun
obtain first-to-fil statu exclus
impact major develop face sever investig relat
price epipen auto-injector compani best sell product octob ceo
heather bresch testifi front congress regard epipen price shortli afterward januari
feder trade commiss file anti-trust investig whether violat anti-trust
law protect epipen competit august reach deal depart
justic regard epipen paid million settlement alleg overcharg
govern epipen misclassifi gener drug avoid pay medicaid rebat result
signific pressur congress consum media launch gener epipen
decemb price discount brand epipen
octob presid rajiv malik identifi target expand lawsuit alleg
price collus across gener drug industri
august acquir sweden-bas meda ab billion inclus net debt believ
meda brand over-the-counter busi specialti drug franchis includ dermatolog respiratori allergi
along strength differ geograph region includ china russia asian countri
provid signific intern growth opportun
market profil world-wide gener drug market estim billion
account global market boost rise demand inexpens gener
throughout world benefit larg number brand drug recent lost patent
protect unbrand brand gener account prescript dispens
 repres total pharmaceut sale dollar accord
financi trend sale aid sever acquisit risen billion
billion repres three-year compound annual growth rate compound-annual-growth-rate howev
sale growth advers impact declin gener drug price adjust ep grew
repres three-year compound-annual-growth-rate howev adjust
ep declin achiev
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued
neutral sinc novemb technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next month posit view
reflect strong novel drug approv activ
see fda posit
brand drug maker repres
lion share sub-industri market
cap view temper expect
continu pressur gener drug price
neg gener drug maker lower
growth overal prescript volum
far year-over-year increas
brand drug price per prescript
around accord iqvia estim
aid strong novel drug approv activ
fda particularli weak year
novel drug approv number
rebound pace
strong growth well approv alreadi
made octob expect strong
pace novel drug approv brand drug
price inflat continu next year
aid estim approxim
year-over-year growth brand pharma
spend year end june
side coin
outlook gener drug price mostli
neg growth gener drug price
averag around neg far
dont expect major near-term
revers trend toward posit price
growth think deflationari trend
mostli driven robust gener drug
approv activ fda custom
consolid rather polit
total gener drug approv hit record
grow year-over-year
increas competit exist gener
view bring price pace
gener approv seem moder
howev approv
august versu
expect moder
deflat howev bring full-on
gener inflat due view
purchas joint ventur
three major drug distributor three largest
 retail pharmaci limit gener maker
abil rais drug price environ
joint ventur account
gener sale estim includ
cardin
walgreen
beyond drug price think prescript
volum growth fall
next year strong gain health insur
growth think
gain harder come
next year unemploy near
all-tim low remov tailwind
prescript volum growth go forward
view assum slower growth
number peopl enrol health insur
plan gener mean slower growth
use total enrol figur eight
largest health insur proxi
estim number individu
famili health insur grew
growth slow
coincid roughli growth
prescript volum far versu
accord iqvia estim
expect slow next year
increas versu rise
composit index year-to-d
octob
rise composit index
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ad epipen gener version list drug shortag due
manufactur issu supplier meridian medic separ
catalyst see includ june fda action date biosimilar
neulasta june fda action date gener advair wixela inhub
rais target line peer
ep estim set ep estim
although see sale continu pressur gener price eros
like mid- high-singl digit lower epipen sale
million encourag potenti launch gener
advair name wixela june respond fda inquiri also
see potenti first biosimilar launch
neulasta gener pegfilgrastim june fda action date
et cfra keep hold opinion share
keep target in-lin peer
forward ep estim ep vs
view lower ep estim sale gener
price eros lower epipen sale cannib gener
epipen higher govern rebat fell european sale aid
meda deal rose see stronger driven gener copaxon sale
week end oct gener copaxon market share
new rx total rx see share rise /jeffrey loo cfa
presid rajiv malik identifi target
expand lawsuit brought forth variou state attorney gener alleg
price collus gener drug firm first time investig
name execut target probe expand firm
six state found evid price fix part
employe fulli stand behind mr malik lawsuit
overhang share sinc late last year believ
expand probe continu advers impact share /jeffrey loo
analyst research note compani news
rais target ep
estim -- histor averag forward price-to-earnings see volum
price pressur continu ep vs
consensu keep ep estim drop
sale yoy led north america na total
drop yoy drop na sale mainli due lower volum relat
fda remedi action requir morgantown wv product site well
increas competit epipen adj oper margin improv howev
mainli reduct sg expens
reduct expens adj pre-tax incom yoy
remain cautiou share yet convinc declin
revenu trend stabil note see stabil
gener price environ think deflat may continu
/colin scarola
et cfra keep hold opinion share nv
keep target line peer
forward ep estim ep vs
estim receiv fda form cite violat
morgantown wv plant began remedi program restructur
includ workforc reduct discontinu product aim
reduc complex facil lower ep estim
ep estim revenu fell sale
north america fell mainli lower epipen sale affect on-going
suppli interrupt discontinu certain product lower price
said evalu wide rang altern think
share under-valued give timet assur
altern implement uncertain much interest may
attract given signific price eros gener epipen sale
announc yesterday june fda identifi
minor defici myl gener version glaxosmithklin
gsk advair disku asthma drug inhal combin
second time set back fda advair gener
expect fda relay complet respons letter june
provid addit detail must resolv said minor
defici unclear long take address minor
defici think possibl approv push back
marketweight overweight cfra lower
 sector marketweight overweight cite
overhang high drug price continu advers impact sale
growth profit increas influenc third parti payer
expect increasingli limit market access drug deem
expens also due repeal individu mandat compon
cbo expect sever million peopl opt obtain insur
advers trickle-down effect pressur hospit bottom
et cfra keep hold opinion share
lower target slightli peer
ep estim price pressur loss
exclus certain product ep vs
estim sale fell north american sale fell sale
europ aid fx benefit rose sale rest
world fx benefit rose north american sale advers
impact loss exclus olmesartan olmesartan hctz lower sale
brand product includ epipen experienc manufactur
delay slower-than-expect sale gener copaxon may fda
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
